News

ISI Technology Makes Inc. 5000 List for the Second Consecutive Year

BUFFALO, N.Y., Sept. 20, 2024 /PRNewswire/ -- ISI Technology, a leading provider of software solutions for Non-Emergency Medical Transportation (NEMT)…

1 year ago

Stryker completes acquisition of NICO Corporation, expanding minimally invasive solutions for brain tumor removal and stroke care

PORTAGE, Mich., USA, Sept. 20, 2024 /PRNewswire/ -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today that it…

1 year ago

XpertDox Partners with Blue Fish Pediatrics to Enhance Medical Coding Efficiency with AI-Powered Healthcare Coding Software

XpertDox and Blue Fish Pediatrics Join Forces to Streamline Medical Coding, Enhance Clinical Documentation, and Boost Reimbursement Potential PHOENIX, Sept.…

1 year ago

This Week in Health News: 11 Stories You Need to See

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including the latest FDA approvals, health…

1 year ago

BioHarvest Sciences Reports Director’s Ongoing Key Role Following Resignation from Board

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - September 20, 2024) - BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) ("BioHarvest" or…

1 year ago

NervGen Pharma to Present at the Unite 2 Fight Paralysis 19th Annual Science & Advocacy Symposium Focused on Spinal Cord Injury

Vancouver, British Columbia--(Newsfile Corp. - September 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company…

1 year ago

Water Tower Research Highlights Ainos VELDONA Clinical Trial for HIV+ Patients with Oral Warts

SAN DIEGO, CA / ACCESSWIRE / September 20, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare…

1 year ago

Nutriband Licenses Bitrex(R) Brand Aversive Agent for Its Lead Product – Aversa(TM) Fentanyl Transdermal Patch

Nutriband signs trademark licensing agreement for Bitrex® brand denatonium benzoate, the most bitter substance in the world, as an aversive…

1 year ago

Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade

European Commission grants conditional marketing authorization for Iqirvo® (elafibranor), first-in-class new treatment for primary biliary cholangitis (PBC), a rare liver…

1 year ago

Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed

Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant,…

1 year ago